BENAZEPRIL HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Benazepril Hydrochloride, and what generic alternatives are available?
Benazepril Hydrochloride is a drug marketed by Amneal Pharms, Ani Pharms, Aurobindo Pharma, Chartwell Rx, Corepharma, Genpharm, Heritage Pharma, Prinston Inc, Rising, Sun Pharm Inds Ltd, Teva, Zydus Lifesciences, Apotex, Aurobindo Pharma Usa, Mylan Pharms Inc, and Sandoz. and is included in nineteen NDAs.
The generic ingredient in BENAZEPRIL HYDROCHLORIDE is benazepril hydrochloride; hydrochlorothiazide. There are fourteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the benazepril hydrochloride; hydrochlorothiazide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Benazepril Hydrochloride
A generic version of BENAZEPRIL HYDROCHLORIDE was approved as benazepril hydrochloride; hydrochlorothiazide by ANI PHARMS on February 11th, 2004.
Summary for BENAZEPRIL HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 16 |
NDAs: | 19 |
Finished Product Suppliers / Packagers: | 26 |
Raw Ingredient (Bulk) Api Vendors: | 99 |
Clinical Trials: | 44 |
Patent Applications: | 1,965 |
Formulation / Manufacturing: | see details |
DailyMed Link: | BENAZEPRIL HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for BENAZEPRIL HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Lupus Research Alliance | Phase 2 |
Northwell Health | Phase 2 |
Shanghai Children's Hospital | Phase 2 |
Pharmacology for BENAZEPRIL HYDROCHLORIDE
Drug Class | Angiotensin Converting Enzyme Inhibitor |
Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
Physiological Effect | Decreased Blood Pressure |